In 258 adults with transfusion-dependent α- or β-thalassaemia, oral mitapivat for 48 weeks gave a transfusion reduction response in 30% vs 13% with placebo (difference 18 points). Discontinuation for adverse events was 6% vs 1%.
RCTn = 258
Cappellini et al. Efficacy and safety of mitapivat in adults with transfusion-dependent α-thalassaemia or β-thalassaemia (ENERGIZE-T): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial